The insurance company will then determine whether the medication is covered. If a drug requires prior authorization but you start treatment without the prior approval, you could pay the full pregabalin online cost of the medication. You can ask your insurance company whether pregabalin requires prior authorization.

Quality Care from Quality Providers

To our knowledge, this study is the first randomized, open-label, pilot trial in which the impact of pregabalin add-on treatment is examined explicitly for NP in cervical myelopathy patients. However, the now increasingly common prescription of these medications by primary care providers may preclude a large-scale study in the future, or a wash-out period may be needed for the discontinuation of pregabalin. Second, the results of this study will lead to a larger, well-controlled, randomized clinical trial regarding the efficacy of pregabalin for the treatment of NP in cervical myelopathy patients before such use becomes permanently engrained among pain physicians.

Gabapentin

Capsaicin 8% patch also remained dominant or cost-effective in the one-way sensitivity analysis. A structural sensitivity analysis showed that the capsaicin 8% patch was the dominant treatment strategy over all time horizons except for 1 year, when the ICER was £1,242 per QALY gained (i.e. highly cost-effective). The probabilistic sensitivity analysis showed that varying model inputs had limited impact on the results, and the probability that the capsaicin 8% patch was cost-effective compared with pregabalin at a willingness-to-pay threshold of £20,000 per QALY was 97%. Pregabalin-treated patients comprised the intervention group, whereas the comparator group received benzodiazepines, SSRIs, SNRIs, or placebo. Efficacy and safety were evaluated using various scales and adverse events (AEs). Outcome measures included the Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression Improvement Scale (CGI-I), discontinuation rates, costs, and quality-adjusted life-years (QALYs).

  • Model inputs included treatment-specific transition probabilities, utility values, and direct and indirect costs for each health state, which were derived from published sources.
  • Beyond placebos, first-line drugs, such as benzodiazepines and SSRI/SNRIs, were included, providing a more complete and practical perspective of pregabalin’s efficacy relative to conventional treatments.
  • For those who rely on Lyrica for managing chronic conditions, reducing the cost of this medication can make a significant difference.
  • These variables contributed to the greatest variation in iNMB estimates, especially for strategies involving amitriptyline (eFigures 2 and 3 in Supplement 1).

According to GoodRx, pregabalin prices can be as low as $10.59 for a 30-capsule supply, a significant saving compared to Lyrica’s branded cost of around $648 for 60 capsules of 50mg. This imports openly accessible prescribing data from the monthly files published by the NHS Business Services Authority (NHSBSA)3 which contain data on cost and volume prescribed for each drug, dose and preparation, for each month, for each English general practice. From this dataset we extracted data on all prescriptions dispensed between April 2013 and July 2016 for pregabalin capsules of any form. Capsaicin 8% patch was the dominant treatment strategy versus pregabalin in six of the seven scenario analyses (Table 4). Only the inclusion of optional topical anesthesia prior to treatment with the capsaicin 8% patch resulted in an incremental cost, but the treatment strategy remained cost-effective (ICER £1,599 per QALY). Duloxetine 120 mg achieved the highest probability of being cost-effective but never exceeded 55% at any WTP threshold.

The threshold analysis showed that in most cases, a value to yield an ICER of £20,000 or £30,000 per QALY could not be determined or was outside a plausible range (Table 5). Capsaicin 8% patch only failed to be cost-effective at a £30,000 per QALY willingness-to-pay threshold when the time to re-treatment was set at less than 60.46 days, or the average number of patches per treatment exceeded 4.10. If the cost of pregabalin was set at £0, the ICER for capsaicin 8% patch versus pregabalin was £17,650 per QALY. The results were presented as incremental cost-effectiveness ratios (ICERs), i.e. cost per quality-adjusted life-year (QALY) gained.